Printer Friendly

Articles from M2 Pharma (November 13, 2019)

1-23 out of 23 article(s)
Title Author Type Words
Alkermes reports USD150m milestone payment on FDA approval of VUMERITY. 224
Bonesupport Holding appoints new GM and EVP Commercial Operations EUROW. 109
Breckenridge wins final FDA approval for launch of generic Tarceva. 153
COI Pharmaceuticals reports purchase of Calporta. 163
Data from Uncontrolled Gout Case Series Supports Immunomodulation with Krystexxa Strategy to Optimize Treatment Outcomes. 401
Genentech's Gazyva, in Combination with Standard of Care, More Than Doubles the percentage of Lupus Nephritis Patients Achieving Complete Renal Response, Compared to Standard of Care Alone. 573
Genentech's Risdiplam Meets Primary Endpoint in Pivotal SUNFISH Trial in People with Type 2 or 3 Spinal Muscular Atrophy. 406
Halozyme Therapeutics reports Q3 2019 financial results. Financial report 166
Kindred Biosciences reports nine months ended 30 September 2019 financial results. 198
LG Chem selects second and third drug targets under expanded partnership with Avacta. 195
Magenta Therapeutics Presents First Immune Reset Results with Antibody-Drug Conjugate Across Multiple Autoimmune Diseases at ACR. 445
Moleculin passes FDA approval to study WP1066 in the treatment of paediatric brain cancer. 169
NEC Corporation signs strategic clinical trial collaboration agreement and equity investment agreement with VAXIMM. 196
PMC Group to acquire organotin specialties business from Lanxess. 173
Promethera Biosciences Presents Updated Clinical Results at AASLD 2019 for World's First Stem Cell Therapy Trial using HepaStem in Acute-on-Chronic Liver Failure. 498
Roche meets primary endpoint in part two Risdiplam SUNFISH trial. 162
Sandoz signs binding agreement to acquire Aspen Global's Japanese business. 152
Sobi announces completion of acquisition of Dova Pharmaceuticals at USD27.5 per share. 287
Tremfya Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies. 313
UroGen Pharma Inks Exclusive License Agreement with Agenus Inc to Advance Treatment of Urinary Tract Cancers. 502
US FDA Accepts for Priority Review Bristol-Myers Squibb's Application for Opdivo Plus Yervoy Combination for Patients with Previously Treated Advanced Hepatocellular Carcinoma. 622
Veloxis Pharmaceuticals swings to profit in first nine months of 2019. 219
Viracta receives FDA's FTD for nanatinostat -valganciclovir combination for treating EBV-associated lymphomas. 214

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters